SCHEMBL3207026

SCHEMBL3207026

CCCCCC[CH]C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
THRB P10828 1/20 0.44
FAAH O00519 2/20 0.42
TRPV1 Q8NER1 1/20 0.42
DNM1 Q05193 3/20 0.41
GMNN O75496 2/20 0.38
USP2 O75604 2/20 0.38
CYP1A2 P05177 2/20 0.38
POLB P06746 2/20 0.38
CYP2C9 P11712 2/20 0.38
APEX1 P27695 2/20 0.38
CYP2C19 P33261 2/20 0.38
RECQL P46063 2/20 0.38
BLM P54132 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
EP300 Q09472 1/20 0.38
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28289397 1.00 TSHR (0.48) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL2287725 1.00 TSHR (0.48) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL11609820 1.00 TSHR (0.48) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL9210803 1.00 TSHR (0.48) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL7391537 1.00 TSHR (0.48) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL9202867 1.00 TSHR (0.48) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL9214895 1.00 TSHR (0.48) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL8714667 1.00 TSHR (0.48) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL9211158 1.00 TSHR (0.48) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL2723911 1.00 TSHR (0.48) TSHRTHRBFAAHTRPV1DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160185724-A1 HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF FAB PHARMA (FR) 2016-06-30 US disclosed
US-8722746-B2 Hydroxyphenyl derivatives and biological applications thereof FAB PHARMA S.A.S. (FR) 2014-05-13 US disclosed
US-20100041658-A1 Hydroxyphenyl Derivatives and Biological Applications Thereof FAB PHARMA (FR) 2010-02-18 US disclosed
EP-1845087-A1 Hydroxyphenyl derivatives and biological applications thereof Mutabilis SA (FR) 2007-10-17 EP disclosed
US-6235771-B1 AIDS THERPAY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 US disclosed
US-6187916-B1 Process for the preparation of taxane derivatives and β-lactam intermediates therefor RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2001-02-13 US disclosed
EP-0938497-A1 CONSTRAINED HELICAL PEPTIDES AND METHODS OF MAKING SAME Genentech, Inc. (US) 1999-09-01 EP disclosed
WO-1998020036-A1 CONSTRAINED HELICAL PEPTIDES AND METHODS OF MAKING SAME GENENTECH, INC. (US) 1998-05-14 WO disclosed
US-5091446-A Amine/acid-modified epoxy resin and curing agent comprising an epoxidized copolyether of a 1,2-alkanediol and 4-vinyl-1,2 cyclohexane; low temperature curing; corrosion resistance KANSAI PAINT CO., LTD. (JP) 1992-02-25 US disclosed
US-4983774-A CATALYZED BY A COPPER COMPOUND SOCIETE NATIONALE ELF AQUITAINE (FR) 1991-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041658-A1 Hydroxyphenyl Derivatives and Biological Applications Thereof HPD, HPGDS, EPX TSHR 4028/4885THRB 3315/4885FAAH 1510/4885
US-20160185724-A1 HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF HPD, HPGDS, EPX TSHR 4028/4885THRB 3315/4885FAAH 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.